Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Extends Offer for Orchid Cellmark

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America announced today that it has extended its tender offer for all of the outstanding shares of Orchid Cellmark until 6:00 p.m., New York City time, on June 15, 2011.

LabCorp announced its $85.4 million offer, or $2.80 per share, to acquire Orchid in April. Less Orchid Cellmark's cash and cash equivalents, and available for sale securities as of Dec. 31, 2010, the price of the deal is worth about $65.6 million.

A couple of weeks ago, LabCorp extended the offer to June 1, 6 p.m. EDT, after the US Federal Trade Commission requested additional information.

As of last night, Orchid shareholders had validly tendered, and not withdrawn, 24.7 million shares of Orchid common stock, including 199,438 shares of Orchid common stock tendered through notices of guaranteed delivery. The shares tendered represent around 82 percent of Orchid's outstanding stock.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.